Jin Medical International Ltd. (ZJYL) 株式分析

企業概要

Jin Medical International Ltd. is engaged in the design, development, manufacture, and sale of wheelchairs and other living aids tailored for individuals with disabilities, the elderly, and those recovering from injuries. The company operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, which implies a specialized focus on essential medical equipment rather than pharmaceuticals or biotechnology. The firm employs a workforce of 273 individuals to support its operations and distribution network. Jin Medical International Ltd. currently holds a market capitalization of $17.22M and reports an annual revenue of $20.69M over the trailing twelve months. These valuation and revenue figures indicate that the company is a small-cap entity with a relatively modest revenue scale compared to larger diversified healthcare conglomerates, positioning it as a niche player in the assistive technology market.

財務健全性

The company reported a revenue of $20.69M and a net income of $1.19M for the trailing twelve months, while generating an EBITDA of $851,585. The significant gap between the revenue figure and the net income reveals a substantial cost structure where operating expenses, taxes, and interest deductibles consume approximately 94.2% of total sales before arriving at the bottom line. The free cash flow stands at $-5,111,959, indicating that the company is currently burning cash, which suggests limited financial flexibility and a reliance on existing cash reserves or external financing to fund operations and capital expenditures. Jin Medical International Ltd. maintains a gross margin of 30.2%, an operating margin of 9.8%, and a profit margin of 5.8%; these figures indicate that while the core manufacturing of wheelchairs retains a healthy portion of revenue, significant overhead costs and potentially high cost of goods sold relative to sales price compress the final profitability. The balance sheet shows a cash position of $29.63M against total debt of $18.91M, resulting in a debt-to-equity ratio of 63.95, which suggests the company carries a leveraged balance sheet where debt obligations exceed equity capitalization. Despite the debt load, the current ratio of 1.85 indicates that the company possesses sufficient current assets to cover its short-term liabilities, pointing to adequate short-term liquidity to meet upcoming obligations. Return on Equity is 4.8% and Return on Assets is 0.8%, metrics that reveal management effectiveness is currently low, as the company struggles to generate substantial returns on the capital invested by shareholders or utilized in its asset base.

バリュエーション評価

The trailing twelve-month P/E ratio is 11.00, while the forward P/E ratio is not available; the absence of a forward P/E implies that analysts or the market currently lack consensus on expected future earnings growth, often due to recent volatility or lack of projected data. The price-to-book ratio is 0.58, which indicates that the market values the company at less than its book value, suggesting that the stock may be trading at a discount relative to the net asset value or that the market discounts the quality and utility of its assets. The price-to-sales ratio is 0.83 and the EV/EBITDA is 7.55, metrics that suggest the company is valued conservatively on a revenue basis but offers a relatively low multiple on earnings before interest, taxes, and depreciation, reflecting the challenges in generating cash flow from operations. The 52-week high is $19.70 and the 52-week low is $1.64, placing the current trading price significantly below the 52-week high and indicating substantial price discovery has occurred over the past year. The beta value is 9.37, which signifies that the stock price exhibits extreme volatility relative to the broader market, moving nearly ten times as much as the market index during periods of fluctuation.

Growth & Income

Revenue growth year over year is -16.5% and earnings growth year over year is -32.0%, indicating that earnings are shrinking at a much faster rate than revenue, which implies that the cost structure is becoming increasingly unsustainable or that pricing power has eroded significantly. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that the firm retains all of its earnings rather than distributing them to shareholders, likely due to the need to preserve cash reserves given the negative free cash flow. The overall growth and income profile is characterized by declining profitability and negative cash generation, with no current income distribution to investors. The company's financial trajectory shows contraction in both top-line sales and bottom-line earnings, creating a challenging environment for capital appreciation or income generation in the near term.